发明名称 Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
摘要 The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.;
申请公布号 US9265773(B2) 申请公布日期 2016.02.23
申请号 US201214343450 申请日期 2012.08.20
申请人 Merck Sharp & Dohme Corp.;MSD Italia S.R.L. 发明人 McComas Casey C.;Liverton Nigel J.;Habermann Joerg;Koch Uwe;Narjes Frank;Li Peng;Peng Xuanjia;Soll Richard;Wu Hao;Palani Anandan;He Shuwen;Dai Xing;Liu Hong;Lai Zhong;London Clare;Xiao Dong;Zorn Nicolas;Nargund Ravi
分类号 A61K31/553;C07D491/052;A61K31/519;A61K31/407;C07D498/22;A61K31/437;C07D491/147;C07D498/14;C07D498/04;A61K31/5365;A61K45/06 主分类号 A61K31/553
代理机构 代理人 Finnegan Alysia A.;Cocuzzo Anna L.
主权项 1. A compound having the formula:or a pharmaceutically acceptable salt thereof,wherein: Q is:  and Y1 is CH and Y2 is N,Y1 is N and Y2 is CH, orY1 is N and Y2 is N; or Q is:  and Z is N, Y1 is CH and Y2 is CH; A is phenyl, 5 or 6-membered heteroaryl, 5 to 7-membered monocyclic cycloalkyl or 5 to 7-membered heterocycloalkyl, each of which can be optionally substituted with up to four R5 groups; V is N or —C(R4)—; W is N or —CH—; X is —(CHR8)n—O— or —C(O)—O—, R1 represents up to 4 optional ring substituents, which can be the same or different, and are independently selected from halo, C1-C6 alkyl, C1-C6 haloalkyl, phenyl, 3 to 7-membered monocyclic cycloalkyl, —O—(C1-C6 alkyl), —O—(C1-C6 haloalkyl) and —CN; R2 is —C(O)N(R6)(R7) or —C(O)O—(C1-C6 alkyl); R3 is H, 4- to 6-membered heterocycloalkyl, 5 or 6-membered heteroaryl, —N(R11)2, halo, —CN, —N(R11)2, —C(O)O—(C1-C6 alkyl) or —N(R9)—S(O)n—R10, wherein said 5 or 6-membered heterocycloalkyl can optionally have one of its ring carbon atoms replaced with a carbonyl group; R4 is selected from H, halo, C1-C6 alkyl, 3 to 7-membered monocyclic cycloalkyl, C1-C6 haloalkyl, —O—(C1-C6 alkyl), —C(OH)—C(O)OR11 and —O—(C1-C6 haloalkyl); each occurrence of R5 is independently selected from H, halo, C1-C6 alkyl, C1-C6 haloalkyl, —O—(C1-C6alkyl), —O—(C1C6 haloalkyl) and —CN, wherein said C1-C6alkyl group can be optionally substituted with —OH or —N(R11)2; R6 and R7 are each independently selected from hydrogen, —C(O)R11, —C(O)OR11, —C(O)C(O)OR11, C1-C6 alkyl, C1-C6 hydroxyalkyl, phenyl, 3 to 7-membered monocyclic cycloalkyl, 3 to 7-membered monocyclic heterocycloalkyl and 5 or 6-membered monocyclic heteroaryl; each occurrence of R8 is independently selected from H, halo, —OH, C1-C6 alkyl, C1-C6 hydroxyalkyl, phenyl, 5 or 6-membered monocyclic heteroaryl, —N(R11)2, C1-C6 haloalkyl, —(C1-C3 alkylene)p-(3 to 7-membered monocyclic cycloalkyl), —(C1-C3 alkylene)p—O—(C1-C6 alkyl), —(C1-C3 alkylene)p—N(R11)2, —(C1-C3 alkylene)—NHC(O)—(C1-C6 alkyl), —(C1-C3 alkylene)—OC(O)(C1-C6 alkyl)NHC(O)O—(C1-C6 alkyl), —(C1-C3 alkylene)—OC(O)—(3 to 7-membered monocyclic heterocycloalkyl), —(C1-C3 alkylene)—NHC(O)(3 to 7-membered monocyclic heterocycloalkyl), —CH(O—(C1-C6 alkyl))2, —O—(C1-C6 haloalkyl), —C(O)OR11, —C(O)N(R11)2, —CH2OC(O)CH(NH2)—(C1-C6 alkyl), —NHS(O)2—(C1-C6 alkyl), —CH2NHCH(R11)C(O)OR11, —NR11—(C1-C3 alkylene)—N(R11)2, —NR11—(C1-C3 alkylene)-(3 to 7-membered monocyclic heterocycloalkyl), —NR11—(C1-C6 hydroxyalkyl) and —CN; R9 is selected from H, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, benzyl, —(C1-C3 alkylene)-(3 to 7-membered monocyclic cycloalkyl) and 3 to 7-membered monocyclic cycloalkyl, wherein said C1-C6 alkyl group can be optionally substituted with a group selected from —N(R11)2, —OR11, —COOH, —C(O)N(R11)2, —S(O)2N(R11)2 and 3 to 7-membered monocyclic heterocycloalkyl and wherein the phenyl moiety of said benzyl group can be optionally substituted with a boronic acid group; R10 is selected from H, C1-C6 alkyl, C1-C6 haloalkyl, phenyl, 3 to 7-membered monocyclic cycloalkyl, 3 to 7-membered monocyclic heterocycloalkyl and 5 or 6-membered monocyclic heteroaryl, wherein said C1-C6 alkyl group can be optionally substituted with a group selected from —N(R11)2, —OR11, —COOH, —C(O)N(R11)2, and —S(O)2N(R11)2; each occurrence of R11 is independently selected from H, C1-C6 alkyl, and 3 to 7-membered monocyclic cycloalkyl; each occurrence of n is 1, 2 or 3; and each occurrence of p is 0 or 1.
地址 Rahway NJ US